comparemela.com

Latest Breaking News On - Locally advanced urothelial - Page 1 : comparemela.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Barcelona
Comunidad-autonoma-de-cataluna
Spain
Beerse
Region-flamande
Belgium
San-antonio
Texas
United-states
Vilaseca
American
Europ-urol

Pembrolizumab Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma

The late-breaking data at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium included the results of KEYNOTE-123 for locally advanced resectable urothelial carcinoma.

United-states
American
National-cancer-institute
Pfizer
Merck-research-laboratories
National-institutes-of-health
Clinical-oncology-genitourinary-cancers
After-surgery
Localized-muscle-invasive-bladder-cancer
Locally-advanced-urothelial
National-cancer

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Vilaseca
Comunidad-autonoma-de-cataluna
Spain
Madrid
Belgium
Beerse
Region-flamande
Barcelona
Indianj-urol
Janssen-cilag-gmb
Janssen-pharmaceutica
Jeffrey-infante

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Spain
Belgium
Madrid
Beerse
Region-flamande
United-kingdom
Janssen-cilag-gmb
Indianj-urol
Kiran-patel
James-wf-catto
Martin-vogel
Janssen-pharmaceutica

Janssen Submits Marketing Authorisation Application to the

Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1 will become the.

Belgium
United-states
Beerse
Region-flamande
American
Janssen-pharmaceutica
Tanakam-sonpavde
Kiran-patel
Janssen-cilag-gmb
Martin-vogel
Clinical-development
Janssen-pharmaceutical-companies

vimarsana © 2020. All Rights Reserved.